A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

NCT03011892 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Ruxolitinib 0.15% Cream QD
DRUG: Ruxolitinib 0.5% Cream QD
DRUG: Ruxolitinib 1.5% Cream QD
DRUG: Ruxolitinib 1.5% Cream BID
DRUG: Triamcinolone 0.1% Cream BID
DRUG: Vehicle Cream BID

Sponsor

Incyte Corporation